Letters To The Editor Open Access
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Jan 6, 2017; 6(1): 57-58
Published online Jan 6, 2017. doi: 10.5527/wjn.v6.i1.57
FGF23 and inflammation
Usama A A Sharaf El Din, Mona M Salem, Dina O Abdulazim, Department of Nephrology, School of Medicine, Cairo University, Nasr City, Cairo 11759, Egypt
Author contributions: The three authors equally shared in writing and revising the letter.
Conflict-of-interest statement: Authors have nothing to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Usama AA Sharaf El Din, MD, Professor, Department of Nephrology, School of Medicine, Cairo University, 58th Abbas El Akkad St., Nasr City, Cairo 11759, Egypt. usamaaas@gmail.com
Telephone: +20-11-11333800 Fax: +20-22-2753890
Received: October 15, 2016
Peer-review started: October 19, 2016
First decision: November 14, 2016
Revised: November 29, 2016
Accepted: December 13, 2016
Article in press: December 14, 2016
Published online: January 6, 2017
Processing time: 73 Days and 20.3 Hours

Abstract

Systemic inflammation is a recognized feature in chronic kidney disease (CKD). The role of systemic inflammation in the pathogenesis of vascular calcification was recently settled. FGF23 was recently accused as a direct stimulus of systemic inflammation. This finding explains the strong association of FGF23 to vascular calcification and increased mortality among CKD.

Key Words: Chronic kidney disease; Inflammation; Vascular calcification; FGF23; Phosphate binders

Core tip: In this letter, the authors confirm the direct offending role of FGF23 in the pathogenesis of vascular calcification and increased mortality among chronic kidney disease patients.
TO THE EDITOR

In the September 6 issue of World J Nephrol, the review article titled “Vascular calcification: When should we interfere in chronic kidney disease patients and how?” showed that the exact pathogenesis of inflammation in chronic kidney disease (CKD) is not fully understood and that many of the inflammatory markers and mediators can promote vascular calcification (VC) in CKD patients. These factors include interleukin 1 (IL-1), IL-6, C-reactive protein and tumor necrosis factor alpha (TNFα)[1-4]. In vivo molecular imaging techniques have disclosed that VC is preceded by inflammation within the arterial wall[5,6]. Similar finding was confirmed by a longitudinal study using positron emission tomography (PET)/computed tomographic (CT) scan[7].

The positive correlation between FGF23 and VC was reported by many groups[8,9]. Similar results were reported in healthy older men, irrespective of traditional risk factors[10] and in children with CKD[11]. Inflammation markers can mitigate the correlation between FGF-23 and vascular calcification[12].

In November issue of kidney international (KI), Singh et al[13] demonstrated that FGF23 stimulates the hepatic secretion of the inflammatory markers IL-6 and C-reactive protein. This finding demonstrates the contribution of FGF23 to the chronic inflammatory status of CKD. It also highlights the role of FGF23 in the vessel inflammation that precedes arterial calcification. In addition, this finding stimulates the energetic control of FGF23 starting in the very early days of stage 2 in CKD patients as we recommended in our review[14]. Lastly, this study supported the value of phosphate binders that can suppress FGF23 and the possible link between such agents and their anti-inflammatory effects and their impact on overall mortality[15-18].

Footnotes

Manuscript source: Unsolicited manuscript

Specialty type: Urology and nephrology

Country of origin: Egypt

Peer-review report classification

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P- Reviewer: Friedman EA, Matowicka-Karna J S- Editor: Ji FF L- Editor: A E- Editor: Lu YJ

References
1.  Sharaf El Din UA, Salem MM, Abdulazim DO. Vascular calcification: When should we interfere in chronic kidney disease patients and how? World J Nephrol. 2016;5:398-417.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 17]  [Cited by in F6Publishing: 13]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
2.  Stompór T, Pasowicz M, Sulłowicz W, Dembińska-Kieć A, Janda K, Wójcik K, Tracz W, Zdzienicka A, Klimeczek P, Janusz-Grzybowska E. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis. 2003;41:203-211.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 112]  [Cited by in F6Publishing: 125]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
3.  Stompór T. An overview of the pathophysiology of vascular calcification in chronic kidney disease. Perit Dial Int. 2007;27 Suppl 2:S215-S222.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006;21:1915-1920.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 78]  [Cited by in F6Publishing: 83]  [Article Influence: 4.6]  [Reference Citation Analysis (0)]
5.  New SE, Aikawa E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. Circ Res. 2011;108:1381-1391.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 1]  [Reference Citation Analysis (0)]
6.  Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117:2938-2948.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 676]  [Cited by in F6Publishing: 759]  [Article Influence: 47.4]  [Reference Citation Analysis (0)]
7.  Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, Brady TJ, Hoffmann U, Tawakol A. Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. Circ Cardiovasc Imaging. 2013;6:747-754.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 112]  [Cited by in F6Publishing: 125]  [Article Influence: 11.4]  [Reference Citation Analysis (0)]
8.  Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25:2679-2685.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 139]  [Cited by in F6Publishing: 148]  [Article Influence: 10.6]  [Reference Citation Analysis (0)]
9.  Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2012;23:2017-2025.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Schoppet M, Hofbauer LC, Brinskelle-Schmal N, Varennes A, Goudable J, Richard M, Hawa G, Chapurlat R, Szulc P. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab. 2012;97:E575-E583.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 62]  [Cited by in F6Publishing: 65]  [Article Influence: 5.4]  [Reference Citation Analysis (0)]
11.  Paoli S, Mitsnefes MM. Coronary artery calcification and cardiovascular disease in children with chronic kidney disease. Curr Opin Pediatr. 2014;26:193-197.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 16]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
12.  Nasrallah MM, El-Shehaby AR, Osman NA, Fayad T, Nassef A, Salem MM, Sharaf El Din UA. The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers. Nephron Extra. 2013;3:106-112.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 30]  [Article Influence: 2.7]  [Reference Citation Analysis (0)]
13.  Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, Di Marco GS. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90:985-996.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 228]  [Cited by in F6Publishing: 268]  [Article Influence: 33.5]  [Reference Citation Analysis (0)]
14.  Lin HH, Liou HH, Wu MS, Lin CY, Huang CC. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology (Carlton). 2014;19:672-678.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 32]  [Cited by in F6Publishing: 35]  [Article Influence: 3.9]  [Reference Citation Analysis (0)]
15.  Zayed BM, Fishawy H, Al-Shihaby AR, Salem MA3, Sharaf El Din UA. Salem MM efficacy of sevelamer hydrochloride and calcium carbonate as phosphate binders on FGF23 and coronary calcification in hemodialysis patients. World Congress of Nephrology 2015, Cape Town, March 13-17.  Available from: http://www.posters2view.eu/wcn2015/lookup_view.php?word=Zayed&where=authors&return=authorindex.php?alpha_index=25&page=1.  [PubMed]  [DOI]  [Cited in This Article: ]
16.  Rao M, Steffes M, Bostom A, Ix JH. Effect of niacin on FGF23 concentration in chronic kidney disease. Am J Nephrol. 2014;39:484-490.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 20]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
17.  Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Donate-Correa J, Cazaña-Pérez V, García-Pérez J. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:2272-2279.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 73]  [Cited by in F6Publishing: 71]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
18.  Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7:487-493.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 173]  [Cited by in F6Publishing: 164]  [Article Influence: 13.7]  [Reference Citation Analysis (0)]